The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Accolade Release 11.2

6 Jul 2017 07:00

RNS Number : 2492K
Sopheon PLC
06 July 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon's Accolade 11.2 Introduces New Analytics Capabilities to Enable Actionable Insights

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Management, announces today the latest version of its Accolade® Enterprise Innovation Management (EIM) solution.

'Good' decisions are based on the availability of 'good' information - having meaningful, trusted and current data at your fingertips at the moment you need it. Business leaders driving decision-centric processes should be drawing on comprehensive information that is generated internally as well as gleaned from outside the company. Sopheon has long focused on surfacing relevant and timely information to support better, faster decisions; with the release of Accolade version 11.2, Sopheon offers new analytic and knowledge discovery capability to more proactively manage risk and create breakthrough innovations with increased efficiency. The new capability - named Accolade Insights - offers a range of benefits.

Further Connecting the Enterprise

Speed to informed decisions, critical in a fast-moving, digital business environment, depends on data that is timely, accurate, situationally aware and actionable. Accolade Insights automatically leverages and connects internal and external data sources to proactively consolidate and serve up intellectual 'assets' at the point a decision needs to be made. These assets include relevant experts and expertise, learnings from past work, and external macroeconomic changes impacting critical assumptions underpinning business forecasts and key performance indicators.

Pre-empting Risk and Improving Accuracy of Business Forecasts

Accolade Insights was designed to help companies leverage internal data in combination with macroeconomic and other external factors for real-time monitoring of the health status of products, portfolios and projects, including the business case assumptions impacting accuracy of revenue and profit forecasts. This is equally applicable to the management of new product introductions, in-market products, product lines and market segments.

When shown a preview of this functionality, a $14 billion industrial manufacturing customer stated: "Some time ago we had what we thought was a great innovation, but the macroeconomics shifted in the middle of our product development cycle. In the end we went to market with a product that failed because we didn't proactively adjust to the shift. Had I had this early visibility of the business case impact of the market dynamics, it would have saved us millions of dollars."

Stimulating Innovation & Improving Efficiency through Proactive Knowledge Reuse

Many companies encounter redundancy of innovation effort. They waste time and money on duplicating work that has been done before; recreating experience that has been 'lost' when key employees have left, repeating the same mistakes project after project because lessons learned are not codified and shared; or not being aware of technology or other developments that could be reused to shorten the time required to develop breakthrough innovations. Accolade automatically captures cross-functional work activity and work product, which become a rich asset for reuse.

One long-standing Sopheon customer proudly relates how a breakthrough technology developed by a packing business unit to retain freshness in bags of crisps, was successfully reused for entirely different applications in aero and auto by another division, generating millions in new revenue. The 'discovery' of the technology that was reused was enabled through Accolade.

 

Sopheon's CEO Andy Michuda, said: "Sopheon has long focused on making relevant and timely information available to support better, faster decisions. Accolade 11.2 automatically leverages and connects internal and external data sources through Accolade Insights, allowing customers to proactively manage risk and create breakthrough innovations with more efficiency."

 

 

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKPDBABKDPOK
Date   Source Headline
21st Feb 20247:00 amRNSCancellation - Sopheon Plc
20th Feb 20244:31 pmRNSScheme of Arrangement becomes Effective
20th Feb 20247:30 amRNSSuspension - Sopheon plc
16th Feb 20241:40 pmRNSIssue of Equity, PDMR Dealing and Rule 2.9
16th Feb 20241:35 pmRNSCourt Sanction of Scheme of Arrangement
16th Feb 20249:04 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
14th Feb 20248:32 amRNSForm 8.5 (EPT/NON-RI)
13th Feb 20245:30 pmRNSSopheon
9th Feb 20243:30 pmRNSForm 8.3 - SPHN LN
9th Feb 20249:35 amRNSForm 8.3 - Sopheon plc
9th Feb 20249:14 amRNSForm 8.5 (EPT/NON-RI)
8th Feb 20242:00 pmRNSResults of Court Meeting and General Meeting
17th Jan 20241:31 pmRNSHolding(s) in Company
17th Jan 20249:42 amRNSForm 8.3 - Sopheon plc
16th Jan 20245:45 pmRNSPublication of Scheme Document
15th Jan 202410:53 amRNSForm 8.3 - Sopheon plc
15th Jan 20248:13 amRNSForm 8.3 - SOPHEON PLC
12th Jan 20243:22 pmRNSForm 8.3 - Sopheon PLC
11th Jan 20248:50 amRNSSatisfaction of NSIA Condition
11th Jan 20248:49 amRNSForm 8.3 - SOPHEON PLC
10th Jan 20249:13 amRNSForm 8.3 - SOPHEON PLC
9th Jan 202412:35 pmRNSForm 8.3 - Sopheon plc
9th Jan 20248:48 amRNSForm 8.3 - SOPHEON PLC
8th Jan 202412:22 pmRNSIssue of Equity
8th Jan 20248:31 amRNSForm 8.3 - SOPHEON PLC
4th Jan 20249:45 amRNSForm 8.3 - SOPHEON PLC
2nd Jan 20245:18 pmRNSForm 8.3 - Sopheon Plc
2nd Jan 20249:07 amRNSForm 8.3 - SOPHEON PLC
22nd Dec 20231:00 pmRNSRecommended Cash Offer
15th Dec 20238:39 amRNSForm 8.5 (EPT/NON-RI)
13th Dec 20238:32 amRNSForm 8.5 (EPT/NON-RI)
12th Dec 202310:55 amRNSForm 8.5 (EPT/NON-RI)
11th Dec 20238:37 amRNSForm 8.5 (EPT/NON-RI)
8th Dec 202310:41 amRNSForm 8.5 (EPT/NON-RI)
6th Dec 20238:36 amRNSForm 8.5 (EPT/NON-RI)
5th Dec 20239:16 amRNSForm 8.5 (EPT/NON-RI)
4th Dec 20236:18 pmRNSRule 2.9 Announcement
4th Dec 202312:30 pmRNSIssue of Equity
28th Nov 20237:00 amRNSOffer update - extension to PUSU Deadline
17th Nov 202311:39 amRNSForm 8.5 (EPT/NON-RI)
15th Nov 20239:30 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20232:59 pmRNSForm 8.3 - SOPHEON PLC
10th Nov 202311:40 amRNSForm 8.5 (EPT/NON-RI)
10th Nov 202311:09 amRNSForm 8.3 - Rivomore Limited - Sopheon plc - Amend
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202312:57 pmRNSForm 8.3 - Sopheon plc
8th Nov 202310:25 amRNSForm 8.5 (EPT/NON-RI) - Sopheon PLC
8th Nov 20237:00 amRNSForm 8 (OPD) Sopheon plc
7th Nov 202311:24 amRNSForm 8.5 (EPT/NON-RI)
6th Nov 20231:03 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.